← Leaderboards
Douglas Edward Peterson
University Of Connecticut Sch Of Med/Dnt
$853,886
Attributed
$3,068,547
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $803.1K · FY2009–13$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$3,068,547 · 5
By mechanism
R01$2,952,881 · 1
R13$60,000 · 2
M01$55,666 · 2
Top collaborators
- Patricia Diaz4 shared
- Anna I Dongari-Bagtzoglou4 shared
- Linda D Strausbaugh4 shared
Most similar at University Of Connecticut Sch Of Med/Dnt
Same institution · by research overlap
- Rajesh V Lalla$9,930,182
- Patricia Diaz$5,206,897
- Linda D Strausbaugh$738,220
- Jonathan M Covault$7,325,948
- Peter James Krause$2,079,888
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchOral MucosaHuman SubjectDigestive DisorderAutologous TransplantationBiopsyStomatitisHematopoietic Tissue TransplantationProstaglandin EProstaglandin AnalogsCell TransplantationCytokineBone Marrow TransplantationChemopreventionCancer TherapyBaseOralCellsAdverse EffectsCancer Radiation TherapyCommunitiesCytotoxicCytotoxicityComplex
Grant awards (21)
The oral microbiome during cancer chemotherapy and its role in oral mucositis$756,222
R01 · FY2013 · DE
2013 Gordon Research Conference: Mucosal Health & Disease$10,000
R13 · FY2013 · DE · contact PI
The oral microbiome during cancer chemotherapy and its role in oral mucositis$803,123
R01 · FY2012 · DE
The oral microbiome during cancer chemotherapy and its role in oral mucositis$715,756
R01 · FY2011 · DE
The oral microbiome during cancer chemotherapy and its role in oral mucositis$677,780
R01 · FY2010 · DE
Oral Complications of Emerging Cancer Therapies$30,000
R13 · FY2009 · DE · contact PI
Oral Complications of Emerging Cancer Therapies$20,000
R13 · FY2009 · DE · contact PI
CYTOKINE DYSREGULATION IN ULCERATIVE ORAL MUCOSITIS IN HEMATOPOIETIC$0
M01 · FY2002 · RR
RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MISOPROSTOL$0
M01 · FY2002 · RR
RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MISOPROSTOL$4,361
M01 · FY2001 · RR
CYTOKINE DYSREGULATION IN ULCERATIVE ORAL MUCOSITIS IN HEMATOPOIETIC$4,361
M01 · FY2001 · RR
CYTOKINE DYSREGULATION IN ULCERATIVE ORAL MUCOSITIS IN HEMATOPOIETIC$0
M01 · FY2001 · RR
RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MISOPROSTOL$0
M01 · FY2001 · RR
RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MISOPROSTOL$0
M01 · FY2001 · RR
CYTOKINE DYSREGULATION IN ULCERATIVE ORAL MUCOSITIS IN HEMATOPOIETIC$0
M01 · FY2001 · RR
CYTOKINE DYSREGULATION IN ULCERATIVE ORAL MUCOSITIS IN HEMATOPOIETIC$19,111
M01 · FY2000 · RR
RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MISOPROSTOL$19,111
M01 · FY2000 · RR
RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MISOPROSTOL$4,361
M01 · FY2000 · RR
RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MISOPROSTOL$4,361
M01 · FY2000 · RR
CYTOKINE DYSREGULATION IN ULCERATIVE ORAL MUCOSITIS IN HEMATOPOIETIC$0
M01 · FY2000 · RR
CYTOKINE DYSREGULATION IN ULCERATIVE ORAL MUCOSITIS IN HEMATOPOIETIC$0
M01 · FY2000 · RR